Pancreatic cancer is one of the most common cancer types with a very poor survival rate. Due to late diagnosis, pancreatic cancer is usually locally advanced and precludes surgical resection, with only a minority of patients responding to radio- and chemotherapy. In addition to conventional photon radiotherapy, particle therapy with carbon ions holds a great promise for the treatment of cancer due to its superior dose distribution, with the highest dose being delivered at the tumor site and limited radiation damage to the healthy surrounding tissue.

At the MedAustron Ion Beam Therapy and Research Center we have access to the synchrotron particle accelerator for carbon ions. In this project we would like to identify new combinatorial treatments with small molecule inhibitors that potentiate the immunogenic effects of radiation. To this end, we will analyse the activation of cGAS/STING, RIG-I/MAVS and type I interferon response following radiation (X-ray and carbon ions) as well as the induction of various non-immunogenic and immunogenic cell death pathways.

Expertise in the following techniques is required for this project: cell culture, molecular biology techniques such as RT-qPCR, ELISA, western blotting, and immunofluorescence microscopy.

We are an interdisciplinary team of biologists and biotechnologists who are keen on harnessing radiation to devise new treatment strategies for cancer: www.sladelab.org. The work will be carried out at MedAustron in Wiener Neustadt. The position is initially for 1 year with the possibility of a 1-year extension. The start date is ASAP. The contract is for 40h/week with the salary of 3.789,00 € (brutto)/month.

Please send your CV, motivation letter and contact information of at least two references to dea.slade(at)meduniwien.ac.at and sylvia.kerschbaum-gruber(at)meduniwien.ac.at

Fachgebiet

Molecular and cell biology (cell culture, RT-qPCR, western blotting, immunofluorescence microscopy)

Arbeitgeber

MedAustron

Stunden

40

Antrittsdatum

01. Jänner 2024

Bewerbungsfrist

31. Dezember 2023

Nach oben scrollen